Studies have shown that patients with FLT3 Internal Tandem Duplication (ITD) and Tyrosine Kinase Domain (TKD) mutations, favorable-risk leukemias, and therapy-related AML (t-AML), or AML with myelodysplasia-related changes (AML-MRC) can benefit from personalized therapy [2-4]. Here, FLT3 is linked to acute myeloid leukemia.